Noramco has acquired Cambrex’s Drug Product Business, known as Halo Pharmaceuticals, bolstering its API manufacturing with new drug formulation, production, and packaging services in Québec and New Jersey. Rebranding to Halo, Noramco now offers end-to-end solutions from clinical to commercial stages. CEO Lee Karras heralds the expansion, emphasizing customer service and integration benefits for nearly 400 new employees within the Noramco family.
Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals. This acquisition will provide API customers of Noramco, and its subsidiary Purisys, with additional service options such as drug product formulation development, clinical and commercial drug product manufacturing, and packaging from facilities in Mirabel, Québec, and Whippany, New Jersey. Noramco is returning to the Halo Pharmaceutical brand as part of this acquisition.
“This acquisition allows Noramco to provide our customers with more sourcing options beyond APIs. With these additional capabilities, Noramco/Purisys customers can develop drug product formulations for their APIs for both clinical and commercial purposes,” said Noramco CEO Lee Karras. “Having previously operated the Halo Pharmaceuticals business, I have a direct appreciation of the capabilities of both sites and look forward to working with existing and future customers while welcoming the almost 400 new employees to the Noramco group of companies.”
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.